Conduit Pharmaceuticals Net Income

The latest net income for CDT is $370M as of June 2026. That compares with $160M in the prior-year period — up 124.2% year over year. That is above the sector sector average of $110M. Investors often review this figure alongside Conduit Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, CDT's net income moved from $160M to $370M — a 124.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Conduit Pharmaceuticals's operating scale or balance-sheet position.

Against its sector companies, CDT currently prints $370M for net income, while the sector average sits near $110M. That is roughly 246.0% above the sector mean. Large gaps often invite a closer look at Conduit Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $370M for CDT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $110M. Explore the charts below for those layers of context.

After noting CDT's net income ($370M), review year-over-year change from $160M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.